{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:40:58Z","timestamp":1788993658074,"version":"build-2803163510"},"reference-count":50,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shanghai \u201cBelt and Road\u201d Joint Laboratory Project","award":["No. 22490750200"],"award-info":[{"award-number":["No. 22490750200"]}]},{"name":"Shanghai \u201cBelt and Road\u201d Joint Laboratory Project","award":["No. 23141902400"],"award-info":[{"award-number":["No. 23141902400"]}]},{"name":"Shanghai \u201cBelt and Road\u201d Joint Laboratory Project","award":["No. XDB0490000"],"award-info":[{"award-number":["No. XDB0490000"]}]},{"name":"Shanghai Laboratory Animal Program","award":["No. 22490750200"],"award-info":[{"award-number":["No. 22490750200"]}]},{"name":"Shanghai Laboratory Animal Program","award":["No. 23141902400"],"award-info":[{"award-number":["No. 23141902400"]}]},{"name":"Shanghai Laboratory Animal Program","award":["No. XDB0490000"],"award-info":[{"award-number":["No. XDB0490000"]}]},{"name":"Strategic Priority Research Program of the Chinese Academy of Sciences","award":["No. 22490750200"],"award-info":[{"award-number":["No. 22490750200"]}]},{"name":"Strategic Priority Research Program of the Chinese Academy of Sciences","award":["No. 23141902400"],"award-info":[{"award-number":["No. 23141902400"]}]},{"name":"Strategic Priority Research Program of the Chinese Academy of Sciences","award":["No. XDB0490000"],"award-info":[{"award-number":["No. XDB0490000"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background\/Objectives: Respiratory syncytial virus (RSV) poses a substantial global health threat, particularly impacting infants and vulnerable pediatric populations through severe respiratory morbidity. Methods: We developed a novel adenoviral vector vaccine platform utilizing chimpanzee adenovirus 68 (AdC68) to deliver prefusion F (pre-F) antigens from RSV subtypes A and B, generating three vaccine candidates: AdC68-A (subtype A), AdC68-B (subtype B), and AdC68-A+B (bivalent formulation). Results: Single intranasal (i.n.) immunization and prime\u2013boost immunizations via intramuscular (i.m.) routes in BALB\/c mice induced robust immune activation, with single i.n. administration conferring durable protection evidenced by an 85% reduction in pulmonary viral loads (p &lt; 0.05) at 134 days post-immunization. All vaccine formulations via i.n. single administration elicited potent subtype-specific IgG responses (geometric mean titers 50\u201312,800) and Th1-polarized cellular immunity (552\u20131201 IFN-\u03b3+ spot-forming units\/106 PBMCs, IgG2a\/IgG1 &gt; 1) in bivalent formulation group, while i.m. boosting enhanced cellular responses 3-fold versus prime immunization alone (p &lt; 0.01). Notably, despite undetectable serum-neutralizing antibodies and absent mucosal IgA in bronchoalveolar lavage at 7 days post-i.n. immunization, the sustained viral control highlights non-neutralizing antibody-mediated protective mechanisms. Conclusions: These findings establish the proof-of-concept for adenoviral-vectored intranasal vaccines against RSV, though optimization of humoral response induction and mucosal immunity duration require further investigation.<\/jats:p>","DOI":"10.3390\/vaccines13050528","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T07:46:49Z","timestamp":1747295209000},"page":"528","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Single-Dose Intranasal Immunization with ChAd68-Vectored Prefusion F Vaccines Confers Sustained Protection Against Respiratory Syncytial Virus in Murine Models"],"prefix":"10.3390","volume":"13","author":[{"given":"Jing","family":"Miao","sequence":"first","affiliation":[{"name":"Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Shanghai 200031, China"},{"name":"University of Chinese Academy of Sciences, Beijing 100049, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejie","family":"Li","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Shanghai 200031, China"},{"name":"University of Chinese Academy of Sciences, Beijing 100049, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1725-0817","authenticated-orcid":false,"given":"Yingwen","family":"Li","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Shanghai 200031, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjing","family":"Mao","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Shanghai 200031, China"},{"name":"University of Chinese Academy of Sciences, Beijing 100049, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenkai","family":"Suo","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Shanghai 200031, China"},{"name":"University of Chinese Academy of Sciences, Beijing 100049, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1242-9866","authenticated-orcid":false,"given":"Jiaming","family":"Lan","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Shanghai 200031, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"ref_1","first-page":"3","article-title":"Respiratory syncytial virus: Virology, reverse genetics, and pathogenesis of disease","volume":"372","author":"Collins","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41579-019-0149-x","article-title":"Respiratory syncytial virus entry and how to block it","volume":"17","author":"Battles","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study","volume":"390","author":"Shi","year":"2017","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/thoraxjnl-2018-212212","article-title":"Respiratory syncytial virus (RSV): A scourge from infancy to old age","volume":"74","author":"Coultas","year":"2019","journal-title":"Thorax"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Fleming, D.M., Taylor, R.J., Lustig, R.L., Schuck-Paim, C., Haguinet, F., Webb, D.J., Logie, J., Matias, G., and Taylor, S. (2015). Modelling estimates of the burden of Respiratory Syncytial virus infection in adults and the elderly in the United Kingdom. BMC Infect. Dis., 15.","DOI":"10.1186\/s12879-015-1218-z"},{"key":"ref_6","unstructured":"Pneumonia Etiology Research for Child Health (PERCH) Study Group (2019). Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: The PERCH multi-country case-control study. Lancet, 394, 757\u2013779."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/infdis\/jiac227","article-title":"Incidence of Respiratory Syncytial Virus Lower Respiratory Tract Infections During the First 2 Years of Life: A Prospective Study Across Diverse Global Settings","volume":"226","author":"Langley","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Martin\u00f3n-Torres, F., Carmo, M., Platero, L., Drago, G., L\u00f3pez-Belmonte, J.L., Bangert, M., D\u00edez-Domingo, J., and Garc\u00e9s-S\u00e1nchez, M. (2022). Clinical and economic burden of respiratory syncytial virus in Spanish children: The BARI study. BMC Infect. Dis., 22.","DOI":"10.1186\/s12879-022-07745-0"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-2600(22)00414-3","article-title":"The burden of respiratory syncytial virus in healthy term-born infants in Europe: A prospective birth cohort study","volume":"11","author":"Wildenbeest","year":"2023","journal-title":"Lancet. Respir. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"See, K.C. (2023). Vaccination for Respiratory Syncytial Virus: A Narrative Review and Primer for Clinicians. Vaccines, 11.","DOI":"10.3390\/vaccines11121809"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","article-title":"Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis","volume":"375","author":"Nair","year":"2010","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.anai.2020.03.017","article-title":"The journey to a respiratory syncytial virus vaccine","volume":"125","author":"Mejias","year":"2020","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41541-023-00734-7","article-title":"The road to approved vaccines for respiratory syncytial virus","volume":"8","author":"Ruckwardt","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa043951","article-title":"Respiratory syncytial virus infection in elderly and high-risk adults","volume":"352","author":"Falsey","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S1473-3099(22)00291-2","article-title":"Respiratory syncytial virus prevention within reach: The vaccine and monoclonal antibody landscape","volume":"23","author":"Mazur","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"134","DOI":"10.37201\/req\/147.2023","article-title":"Respiratory syncytial virus: A new era","volume":"37","year":"2024","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2217\/fvl-2020-0174","article-title":"Nanoparticle vaccines against respiratory syncytial virus","volume":"15","author":"Stephens","year":"2020","journal-title":"Future Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cytogfr.2022.10.001","article-title":"Development of mRNA vaccines against respiratory syncytial virus (RSV)","volume":"68","author":"Qiu","year":"2022","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Kerstetter, L.J., Buckley, S., Bliss, C.M., and Coughlan, L. (2020). Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.607333"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5654","DOI":"10.1128\/JVI.76.11.5654-5666.2002","article-title":"Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology","volume":"76","author":"Zhang","year":"2002","journal-title":"J. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1128\/jvi.69.4.2667-2673.1995","article-title":"Respiratory syncytial virus matures at the apical surfaces of polarized epithelial cells","volume":"69","author":"Roberts","year":"1995","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12016-013-8368-9","article-title":"Respiratory syncytial virus--a comprehensive review","volume":"45","author":"Borchers","year":"2013","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1099\/jgv.0.000959","article-title":"ICTV Virus Taxonomy Profile: Pneumoviridae","volume":"98","author":"Rima","year":"2017","journal-title":"J. Gen. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1086\/429695","article-title":"Respiratory syncytial virus-specific CD8+ memory T cell responses in elderly persons","volume":"191","author":"Heidema","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1046\/j.1365-2567.2003.01619.x","article-title":"Identification of a novel human leucocyte antigen-A*01-restricted cytotoxic T-lymphocyte epitope in the respiratory syncytial virus fusion protein","volume":"108","author":"Rock","year":"2003","journal-title":"Immunology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"309ra162","DOI":"10.1126\/scitranslmed.aac4241","article-title":"Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera","volume":"7","author":"Ngwuta","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1073\/pnas.1115941109","article-title":"Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention","volume":"109","author":"Magro","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1056\/NEJMoa2106062","article-title":"Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy","volume":"386","author":"Center","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.aav9033","article-title":"A proof of concept for structure-based vaccine design targeting RSV in humans","volume":"365","author":"Crank","year":"2019","journal-title":"Science"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S1473-3099(18)30292-5","article-title":"The respiratory syncytial virus vaccine landscape: Lessons from the graveyard and promising candidates","volume":"18","author":"Mazur","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.immuni.2019.08.007","article-title":"Immunological Lessons from Respiratory Syncytial Virus Vaccine Development","volume":"51","author":"Ruckwardt","year":"2019","journal-title":"Immunity"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJMoa1410863","article-title":"Chimpanzee Adenovirus Vector Ebola Vaccine","volume":"376","author":"Ledgerwood","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1473-3099(20)30019-0","article-title":"Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: A randomised, observer-blind, placebo-controlled, phase 2 trial","volume":"20","author":"Tapia","year":"2020","journal-title":"Lancet. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41541-020-0163-z","article-title":"Modified mRNA\/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection","volume":"5","author":"Espeseth","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1016\/j.vaccine.2015.08.056","article-title":"Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats","volume":"33","author":"Widjojoatmodjo","year":"2015","journal-title":"Vaccine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41541-020-0200-y","article-title":"Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice","volume":"5","author":"Bolder","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/infdis\/jiaa193","article-title":"Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged \u226560 Years","volume":"222","author":"Williams","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/infdis\/jiab003","article-title":"Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study","volume":"226","author":"Sadoff","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41421-021-00360-4","article-title":"Heterologous prime-boost immunizations with chimpanzee adenoviral vectors elicit potent and protective immunity against SARS-CoV-2 infection","volume":"7","author":"Liu","year":"2021","journal-title":"Cell Discov."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41541-023-00762-3","article-title":"Both chimpanzee adenovirus-vectored and DNA vaccines induced long-term immunity against Nipah virus infection","volume":"8","author":"Lu","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_47","first-page":"1582","article-title":"Effect of intranasal immunization with soluble tachyzoites antigen in combination with propolis and IFN-\u03b3 on antibody levels in mice","volume":"27","author":"Liu","year":"2011","journal-title":"Chin. J. Public Health"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41590-024-01743-x","article-title":"Mucosal vaccine-induced cross-reactive CD8(+) T cells protect against SARS-CoV-2 XBB.1.5 respiratory tract infection","volume":"25","author":"Ying","year":"2024","journal-title":"Nat. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nri3251","article-title":"Recent progress in mucosal vaccine development: Potential and limitations","volume":"12","author":"Lycke","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41541-024-00857-5","article-title":"An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza","volume":"9","author":"Xing","year":"2024","journal-title":"NPJ Vaccines"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/5\/528\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:33:14Z","timestamp":1760031194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/5\/528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["vaccines13050528"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13050528","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]}}}